Podcast

Treating Early-Stage HER2-Positive Breast Cancer

Author(s):

OncLive Staff

Dr Gradishar and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
Adam M. Brufsky, MD, PhD, FACP
Sara M. Tolaney, MD, MPH
Chirag Shah, MD
Jason A. Mouabbi, MD
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Shipra Gandhi, MD
A panel of 5 experts on breast cancer
A panel of 5 experts on breast cancer
Related Content
Sara M. Tolaney, MD, MPH
July 26th 2024

From Targetless to Targetable, Breakthroughs Push Forward in TNBC Treatment Landscape

David Miller, MD, professor, chief, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Amy and Vernon R. Faulconer Distinguished Chair in Gynecologic Oncology, University of Texas (UT) Southwestern Medical School; medical director, UT Southwestern Harold C. Simmons Cancer Center
July 25th 2024

Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer

Lajos Pusztai, MD, DPhil
July 25th 2024

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

Nam Bui, MD, sarcoma specialist, clinical assistant professor, medicine, Stanford Cancer Institute; Ciara Kelly, MBBCh, BAO, interim clinical director, Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center
July 18th 2024

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

Priscilla F. McAuliffe, MD, PhD, of UPMC Hillman Cancer Center
July 24th 2024

Novel Prompt Shows Potential to Decrease Overtreatment in Older Patients With Early-Stage Breast Cancer

Lisa Conte
July 23rd 2024

Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy